How to Control Asthma with Personalized Management: Where Do We Stand Now?

How to Control Asthma with Personalized Management: Where Do We Stand Now? Curr Drug Metab. 2018 Jan 28;: Authors: Wang M, Yao Y, Jiang S, Tao F, Tang R, Sun J Abstract Asthma is one of the most significant diseases worldwide and causes overwhelming costs physically and economically. The heterogeneity of asthma has been a hot topic, and an increasing amount of research has been conducted on this issue. The study of asthma has revealed various groups of asthma patients who share phenotypic characteristics that naturally elicit the need for personalized asthma therapy. Clinical evidence has shown that a 'one size fits all' approach does not apply to all asthma patients because of the large variability in treatment responses to asthma medication. Attention should be given to patients who do not respond to normal treatment to avoid increasing the risk of exacerbation and meaningless costs. An increasing amount of pharmacogenetics research, genotype-based trials and precision medicine trials have been conducted to investigate this problem. Our review will focus on the three most widely used treatments for asthma management, which are b-adrenergic receptor agonists, inhaled corticosteroids (ICS) and anti-leukotriene modifiers. We summarize the existing loci reported in the literature that are potentially associated with drug responses to typically used medications, suggesting that a genetic test with high predictive accuracy could predict ...
Source: Current Drug Metabolism - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Metab Source Type: research